Nystatin (Fungicidin) |
| Catalog No.GC10090 |
Nystatin (Fungicidin) is an orally active polyene antifungal antibiotic effective against yeast and mycoplasma.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 1400-61-9
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Nystatin (Fungicidin) is a polyene antifungal antibiotic [1].
Antifungal antibiotic is a pharmaceutical fungicide used to treat and prevent mycoses.
Nystatin is a polyene antifungal antibiotic that is effective against yeast and mycoplasma [1]. In liquid media, Nystatin inhibited C. albicans at concentrations of 5-20 U/ml[2].
In a 200 clinical isolates, which comprised of 113 Candida albicans, 54 Candida glabrata, 11 Candida parapsilosis, 11 Candida tropicalis and 11 Candida krusei. Nystatin exhibited MIC90 value of 4 mg/L against C. albicans isolates and all non-albicans Candida species tested. The results confirmed C. Albicans was most frequently susceptible and Nystatin could be used to treat vulvovaginal candidiasis caused by non-albicans Candida species. Nystatin would be an important choice for women affected by non-albicans Candida species which present higher resistance to the imidazole-based treatments [3].
References:
[1]. Childs AJ. Effect of Nystatin on Growth of Candida albicans During Antibiotic Therapy. Br Med J, 1956, 1(4968): 660-662.
[2]. Stewart GT. Laboratory and Clinical Studies with Nystatin in Post-antibiotic Mycotic Infections. Br Med J, 1956, 1(4968): 658-660.
[3]. Choukri F, Benderdouche M, Sednaoui P. In vitro susceptibility profile of 200 recent clinical isolates of Candida spp. to topical antifungal treatments of vulvovaginal candidiasis, the imidazoles and nystatin agents. J Mycol Med, 2014, 24(4): 303-307.
| Cell experiment [1]: | |
|
Cell lines |
Oral Candida species and human buccal epithelial cells |
|
Preparation method |
The solubility of this compound in DMSO is > 30.5 mg/mL. General tips for obtaining a higher concentration: Please warm the tube at 37 °C for 10 minutes and/or shake it in the ultrasonic bath for a while. Stock solution can be stored below - 20 °C for several months. |
|
Reacting condition |
1 hr |
|
Applications |
The minimal inhibitory concentrations (μg/mL) of Nystatin for C. albicans, C. tropicalis, C. krusei, C. parapsilosis, C. glabrata and C. guilliermondii in RPMI broth were 0.78 ~ 1.56, 1.56 ~ 3.12, 3.12, 1.56 ~ 3.12, 0.78 ~ 1.56 and 0.39 ~ 0.78, respectively. Compared with the control group, Nystatin significantly reduced adhesion of 6 Candida species to buccal epithelial cells. However, the adhesion of C. albicans isolates was least affected by Nystatin treatment, which was significantly different from that of the non-albicans species. |
| Animal experiment [2]: | |
|
Animal models |
Aspergillus-infected, neutropenic mice |
|
Dosage form |
2, 4, 6 and 8 mg/kg/day; i.v. |
|
Applications |
At a dose as low as 2 mg/kg/day, Liposomal Nystatin significantly protected neutropenic mice from Aspergillus-induced death compared to either the no-treatment, the saline or the empty-liposome group. Liposomal Nystatin-treated mice showed no evidence of Aspergillus infection either at day 5 in all of the treatment groups or at day 52 in the 8 mg/kg/day liposomal-Nystatin treatment group. |
|
Other notes |
Please test the solubility of all compounds indoor, and the actual solubility may slightly differ with the theoretical value. This is caused by an experimental system error and it is normal. |
|
References: [1]. Ellepola AN, Panagoda GJ, Samaranayake LP. Adhesion of oral Candida species to human buccal epithelial cells following brief exposure to nystatin. Oral Microbiol Immunol. 1999 Dec;14(6):358-63. [2]. Wallace TL, Paetznick V, Cossum PA, Lopez-Berestein G, Rex JH, Anaissie E. Activity of liposomal nystatin against disseminated Aspergillus fumigatus infection in neutropenic mice. Antimicrob Agents Chemother. 1997 Oct;41(10):2238-43. |
|
| Cas No. | 1400-61-9 | SDF | |
| Chemical Name | (4E,6E,8E,10E,14E,16E,18S,19R,20R,21S,35S)-3-[(2S,3S,4S,5S,6R)-4-amino-3,5-dihydroxy-6-methyloxan-2-yl]oxy-19,25,27,29,32,33,35,37-octahydroxy-18,20,21-trimethyl-23-oxo-22,39-dioxabicyclo[33.3.1]nonatriaconta-4,6,8,10,14,16-hexaene-38-carboxylic acid | ||
| Canonical SMILES | CC1C=CC=CCCC=CC=CC=CC=CC(CC2C(C(CC(O2)(CC(C(CCC(CC(CC(CC(=O)OC(C(C1O)C)C)O)O)O)O)O)O)O)C(=O)O)OC3C(C(C(C(O3)C)O)N)O | ||
| Formula | C47H75NO17 | M.Wt | 926.09 |
| Solubility | ≥ 30.45 mg/mL in DMSO | Storage | -20°C, sealed storage, away from moisture and light,unstable in solution, ready to use. |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 1.0798 mL | 5.399 mL | 10.7981 mL |
| 5 mM | 0.216 mL | 1.0798 mL | 2.1596 mL |
| 10 mM | 0.108 mL | 0.5399 mL | 1.0798 mL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 20 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *